Investment Insights: Alphabet and Eli Lilly
-
Alphabet’s recent dividend introduction might still be fresh, but its robust business model and growth potential suggest it’s here to stay.
-
Eli Lilly, on the other hand, has been seeing impressive sales growth and has a strong history of boosting dividends over the last decade.
When it comes to investing, there are various strategies. Some investors chase after stocks expected to grow rapidly, while others prefer companies that provide regular dividends. However, these methods aren’t always mutually exclusive. Certain companies can indeed offer both avenues: growth and consistent income.
This is the case for Alphabet and Eli Lilly. They present compelling options for those aiming to balance growth with dividend income.
Alphabet wasn’t a dividend stock for quite some time, starting its dividend payments just last year and raising it by 5% since then. While its dividend history is brief, the company’s solid fundamentals should help sustain its dividend. Alphabet leads in various sectors, notably in digital advertising, where it has a strong grip on online search and generates substantial revenue annually, with steady growth on the horizon.
In fact, Alphabet’s revenue for Q3 surged by 16% from the previous year, reaching $102.3 billion. This marks the first instance of its quarterly sales surpassing $100 billion, a substantial increase from around $50 billion five years ago. That’s roughly a 15% average annual growth rate. Earnings per share also jumped by 35.4% to $2.87 compared to last year.
As of Q3, Alphabet’s cloud backlog stood at $155 billion, up 46% from the previous quarter. With a strong push in cloud services and AI, alongside expanding Google subscriptions, Alphabet remains an enticing growth stock, holding a market cap of $3.4 trillion. Its robust performance and ability to deliver free cash flow help sustain its solid dividend.
Shifting to Eli Lilly, it’s hard to overlook its remarkable performance in the pharmaceutical sector. This company has been generating sales growth typically associated with smaller tech firms. In Q3, its sales soared by 54% to $17.6 billion, driven by its successful innovations in the GLP-1 market. For instance, its tirzepatide was the first drug approved by the FDA that mimics two hormones, making it more effective than alternatives.
Several factors point to Eli Lilly’s ongoing success. The weight management sector is expanding at breakneck speed, so even with competition rising, tirzepatide likely has a bright future. The company plans to roll out new products like orforglipron, potentially one of the first oral weight loss medications after completing its Phase 3 trials this year. Oral treatments are generally cheaper to produce and transport, which could widen access. Moreover, Eli Lilly is also pushing innovations in oncology and is investing heavily in AI.
The firm is developing the pharmaceutical industry’s most powerful supercomputer, likely to accelerate drug development dramatically. Given these driving forces, Eli Lilly’s future appears promising. Regarding dividends, the company has increased payouts by an impressive 194% over the past decade, making it a standout in the pharmaceutical field for both growth and dividends.
Before considering investing in Alphabet, it’s worthwhile to reflect on a few points:
- If you’re exploring solid stocks, Alphabet isn’t on the best list current analysts have compiled. There might be other opportunities that could yield greater returns in the coming years.
In conclusion, both Alphabet and Eli Lilly offer different pathways for investors, whether pursuing growth or reliable profits. Yet, with the evolving market landscape, staying informed is key.
